Observational studyMedical science monitor : international medical journal of experimental and clinical research2026
Adjunctive Anti-VEGF Therapy Influences on Early Visual Recovery Without Affecting Long-Term Outcomes or Intraocular Pressure After Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy.
Observational study in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND We evaluated the effect of adjunctive anti-vascular endothelial growth factor (anti-VEGF) therapy on postoperative visual recovery and intraocular pressure in patients undergoing pars plana vitrectomy (PPV) for intravitreal hemorrhage as a complication of proliferative diabetic retinopathy. MATERIAL AND METHODS This retrospective observational cohort study included 149 eyes with proliferative diabetic retinopathy that underwent PPV at a tertiary ophthalmology center. Patients were divided into 2 groups according to the use of adjunctive anti-VEGF therapy: 33 eyes received anti-VEGF treatment and 116 underwent PPV without anti-VEGF administration. Best-corrected visual acuity (BCVA, logMAR), and intraocular pressure were assessed preoperatively and at 1 and 6 months after surgery. Changes in BCVA over time were analyzed using a linear mixed-effects model with time, anti-VEGF treatment, and their interaction as fixed effects and patient as a random effect. Arterial hypertension was included as a covariate. RESULTS At 1 month after surgery, patients receiving anti-VEGF therapy demonstrated significantly better BCVA values compared with untreated patients (P<0.05). However, no significant differences in BCVA were observed between groups after 6 months (P>0.05). In the adjusted mixed-effects model, follow-up time was significantly associated with BCVA improvement, whereas anti-VEGF treatment was not independently associated with visual outcomes, and no significant interaction between treatment and time was identified. No significant differences in intraocular pressure were observed between groups either before or after surgery. CONCLUSIONS Adjunctive anti-VEGF therapy may accelerate early visual recovery after PPV without influencing long-term visual outcomes or intraocular pressure, supporting its safety as a perioperative adjunct in vitreoretinal surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.